A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102

NCT03636477 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma

Interventions

BIOLOGICAL: Ad-RTS-hIL-12
DRUG: veledimex
DRUG: Nivolumab

Sponsor

Alaunos Therapeutics